NYSE:ABTMedical Equipment
Abbott Broadens Cardiology And Oncology Reach As Valuation Questions Persist
Abbott Laboratories (NYSE:ABT) received CE Mark approval for its TactiFlex Duo ablation catheter for atrial fibrillation in Europe.
The company is expanding further into pulsed field ablation with this dual mode catheter for heart rhythm management.
Abbott also announced an acquisition of Exact Sciences to enter the cancer diagnostics market.
Abbott shares last closed at $120.73, with a 1 year return of 4.4% and a 3 year return of 15.4%. The company is already a large player in medical...